A platelet-derived growth factor recombinant vaccine for treating pulmonary fibrosis and its application

Abstract

The invention discloses a platelet-derived growth factor (PDGF) recombinant vaccine for treating pulmonary fibrosis, wherein the PDGF epitope (aa72‑87, QVRKIEIVRKKPIFKK) is inserted into the prokaryotic prokaryotic of Pyrococcus furiosus thioredoxin (PfTrx) In the plasmid pET28‑PfTrx, express and purify the recombinant vaccine PfTrx‑PDGF 16 (72‑87), the recombinant vaccine can successfully stimulate the body to produce high-titer anti-PDGF neutralizing antibodies, and significantly reduce the lung fibrosis in mice induced by bleomycin (BLM). PfTrx‑PDGF 16 (72‑87) Recombinant vaccine immunization can significantly reduce the inflammatory response of the lung tissue in the acute stage after tracheal infusion of bleomycin, inhibit the production of collagen and the increase and deposition of cell matrix in the mouse lung; at the same time, it can also reduce the TGF in the lung tissue of the mouse ‑β1, CTGF, α‑SMA, Col1a2, Col3a1 expression levels, these characteristics are extremely beneficial to slow down the process of pulmonary fibrosis.

Description

technical field [0001] The invention belongs to the field of drugs for treating pulmonary fibrosis, and in particular relates to a platelet-derived growth factor recombinant vaccine for treating pulmonary fibrosis and its application. Background technique [0002] Pulmonary fibrosis (or called pulmonary interstitial fibrosis, pulmonary fibrosis, PF) is the end-stage change of a large class of lung diseases characterized by fibroblast proliferation and accumulation of a large amount of extracellular matrix, accompanied by inflammatory damage and tissue structure destruction. The course of the disease is mostly chronic. Common causes of PF include environmental, occupational, physical and chemical factors, such as asbestos, dust, drugs, radiation injury, and inhalation of harmful gases. Some immune diseases such as systemic lupus erythematosus, Sjogren's syndrome, dermatomyositis, scleroderma, etc. can also be accompanied by PF. PF mostly occurs at the age of 40-50, and most...

AI Technical Summary

Problems solved by technology

However, the initial investment in vaccine preparation is large, and appropriate epitopes and carriers need to be selected. Whether the prepared vaccine is immunogenic can stimulate the body to produce high-titer targeted antibodies, and whether the produced antibodies can neutralize pathogenic cytokines. The activity of PDGF and whether it can inhibit the progression of the disease requires a large number of experimental verifications. Therefore, there are relatively few studies on the role of vaccines to inhibit pathogenic cytokines. At present, there is no vaccine against PDGF to treat pulmonary fibrosis.

Images